Lung Cancer Dispatch
Follow
Find tag "ganetespib"
3.7K views | +3 today
Lung Cancer Dispatch
News for Patients and Physicians
Curated by Cancer Commons
Your new post is loading...
Your new post is loading...
Scooped by Cancer Commons
Scoop.it!

Synta Announces Results from Final Analysis of the GALAXY-1 Trial of Ganetespib in NSCLC

Synta Announces Results from Final Analysis of the GALAXY-1 Trial of Ganetespib in NSCLC | Lung Cancer Dispatch | Scoop.it

"Synta Pharmaceuticals Corp. (NASDAQ: SNTA) today announced final results from the GALAXY-1 trial, a global, randomized, multi-center study designed to identify the patients with advanced non-small cell lung cancer (NSCLC) with adenocarcinoma histology most likely to benefit from second-line treatment with the Company’s lead drug candidate, the Hsp90 inhibitor ganetespib, in combination with docetaxel versus docetaxel alone. Ganetespib is a next-generation inhibitor of the chaperone protein Hsp90, which is critical for the activation and stability of numerous proteins that drive cancer growth and proliferation. Ganetespib has been studied in over 1000 patients to date."


Editor's note: This story is about clinical trials designed to test the drug ganetespib in people with non-small cell lung cancer (NSCLC). The drug manufacturer (Synta) recently reported updated results for one of the trials, GALAXY-1. The results confirm that the researchers were able to identify patients who were most likely to benefit from a treatment that combines ganetespib with the chemotherapy drug docetaxel.

Cancer Commons's insight:

Synta  |  May 8, 2014

more...
No comment yet.
Suggested by Cancer Commons
Scoop.it!

Two New Trials of Mesothelioma Treatments Begin in the UK

Mesothelioma is a form of lung cancer strongly associated with exposure to asbestos. Even though asbestos has been banned or heavily regulated in most developed nations, due to delayed onset, the number of mesothelioma cases is predicted to climb until around 2020. In the UK, which has the highest mesothelioma incidence worldwide, two new clinical trials are aiming to find treatments for the disease. The Meso2 trial will investigate ganetespib, while the COMMAND trial will examine defactinib. Defactinib specifically targets cancer stem cells, which often survive cancer treatment and cause cancer recurrence. The drug may therefore help prevent relapse after first-line therapy.

Cancer Commons's insight:

ScienceDaily | Sep 23, 2013

more...
No comment yet.
Suggested by Cancer Commons
Scoop.it!

New Cancer Drug Ganetespib May Extend Survival in Late-Stage Lung Cancer

New Cancer Drug Ganetespib May Extend Survival in Late-Stage Lung Cancer | Lung Cancer Dispatch | Scoop.it

The new cancer treatment ganetespib produced encouraging results in a phase II/III clinical trial examining its effectiveness on late-stage lung adenocarcinoma, a form of non-small cell lung cancer (NSCLC). Patients received ganetespib in combination with docetaxel (Taxotere) or Taxotere alone. Ganetespib treatment resulted in longer overall survival (9.8 months compared to 7.4 months in Taxotere-only patients). Ganetespib inhibits a protein called Hsp90 that acts as a so-called molecular chaperone: it helps different proteins assume their final shape, thus allowing them to function. Many proteins 'chaperoned' by Hsp90 can drive tumor growth in cancer. Researchers hope that blocking Hsp90 with ganetespib will be effective even in patients who have developed mutations that make them resistant to other anticancer drugs, because even the mutated proteins likely still need Hsp90 to function. An ongoing phase III clinical trial seeks to confirm these results.

Cancer Commons's insight:

Medical Xpress | Jun 3, 2013

more...
No comment yet.
Suggested by Cancer Commons
Scoop.it!

Novel Drugs Show Promise in Non-Small Cell Lung Cancer

Novel Drugs Show Promise in Non-Small Cell Lung Cancer | Lung Cancer Dispatch | Scoop.it

Medical experts at the 2012 Chemotherapy Foundation Symposium presented data on the growing number of targeted treatments for non-small cell lung cancer (NSCLC) with so-called driver mutations—specific genetic mutations that drive tumor growth. Among the drugs showing promise in adenocarcinoma are ridaforolimus for KRAS-mutant tumors, ganetespib for ALK- or KRAS-mutant tumors, and afatinib for EGFR-mutant tumors. For squamous cell carcinoma (SCC), new potential treatments include AZD4547 and BGJ398 (FGFR1-mutant), dasatinib and nilotinib (DDR2 mutant), Tarceva and Iressa (EGFRvIII-mutant), and Yervoy and Cadi-05 (all SCC), while anti–PD-1 antibodies such as BMS-936558 may be effective for both adenocarcinoma and SCC.

Cancer Commons's insight:

OncLive | Jan 14, 2013

more...
No comment yet.
Suggested by Cancer Commons
Scoop.it!

Trial Results for New Lung Cancer Drug Ganetespib Leave Some Skeptical

Trial Results for New Lung Cancer Drug Ganetespib Leave Some Skeptical | Lung Cancer Dispatch | Scoop.it

The GALAXY-1 clinical trial examines patients with advanced lung adenocarcinoma, a type of non-small cell lung cancer (NSCLC), receiving either ganetespib (a new cancer drug) and docetaxel (Taxotere, a chemotherapy drug) or Taxotere alone as second-line treatment. Recent interim results show ganetespib-treated patients surviving 10.4 months on average (vs 8.4 months in the Taxotere-only group) and experiencing a 10% reduction in the risk of death. This is a smaller difference than was seen in preliminary results in September, 2012 and June, 2013 (31% and 18% reduction in risk of death, respectively). It is also unclear whether the effect is indeed caused by ganetespib or due to chance. However, the drug’s makers emphasize that ganetespib may be more effective in certain patient subgroups.

Cancer Commons's insight:

The Street | Oct 27, 2013

more...
No comment yet.
Suggested by Cancer Commons
Scoop.it!

FDA Puts Lung Cancer Drug Ganetespib on Fast Track

FDA Puts Lung Cancer Drug Ganetespib on Fast Track | Lung Cancer Dispatch | Scoop.it

Ganetespib, a potential new treatment for non-small cell lung cancer (NSCLC), has been granted Fast Track status by the U.S. Food and Drug Administration (FDA). Fast Track status, reserved for drugs aimed at serious conditions with unmet treatment needs, provides for closer FDA guidance during the drug development process and quicker review for approval. Two clinical trials, GALAXY-1 and GALAXY-2, are currently examining the use of ganetespib in combination with the chemotherapy agent Taxotere (docetaxel) for treating advanced lung adenocarcinoma, a type of NSCLC. Ganetespib acts by blocking Hsp90, a protein that facilitates several components of tumor development and spread.

Cancer Commons's insight:

MarketWatch | Sep 12, 2013

more...
No comment yet.
Suggested by Cancer Commons
Scoop.it!

New Lung Cancer Drug Ganetespib Shows Mixed Results in Clinical Trial

New Lung Cancer Drug Ganetespib Shows Mixed Results in Clinical Trial | Lung Cancer Dispatch | Scoop.it

Results from an ongoing phase II clinical trial suggest that the new drug ganetespib may be effective in a subset of patients with advanced non-small cell lung cancer (NSCLC). People with mutations in the genes EGFR or KRAS, who had been the original focus of the study, did not benefit significantly from the drug. However, among patients with mutations in the ALK gene who had not been treated previously with crizotinib (Xalkori), half seemed to benefit from ganetespib. This finding is based on a small number of patients, but Synta Pharmaceuticals, the company developing ganetespib, will investigate it further in a clinical trial focusing specifically on ALK-mutant NSCLC.

Cancer Commons's insight:

Clinical Cancer Research | Apr 3, 2013

more...
No comment yet.